SORAFENIB

作品数：318被引量：1563H指数：18
导出分析报告
相关领域：医药卫生更多>>
相关作者：曾普华郜文辉刘霞孙惠川汤钊猷更多>>
相关机构：湖南中医药大学福建医科大学中山大学复旦大学更多>>
相关期刊：更多>>
相关基金：国家自然科学基金中国博士后科学基金广东省自然科学基金国家重点基础研究发展计划更多>>
-
在结果中检索

检索结果分析

结果分析中...
选择条件：
  • 期刊=Journal of Cancer Therapyx
共 条 记 录，以下是1-7
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Outcome Results of Treatment with Selective Internal Radiation Therapy (SIRT) in Patients with Hepatocellular Carcinoma: A Single Center Experience
《Journal of Cancer Therapy》2017年第4期349-359,共11页Jan Pfeiffenberger Tatjana Zimmermann Daniel N. Gotthardt Christoph Springfeld Wolfgang Stremmel Peter Schirmacher Henning Schulze-Bergkamen Arianeb Mehrabi Christoph W. Michalski Katrin Hoffmann Nikolas Kortes Boris Radeleff Uwe Haberkorn Clemens Kratochwil Karl Heinz Weiss Carsten Grüllich 
Background: Hepatocellular carcinoma (HCC) has a poor prognosis. Selective internal radiation therapy (SIRT) with microspheres is a treatment option for HCC. This study aimed to assess safety and survival (OS) in pati...
关键词：SIRT SORAFENIB LIVER Cancer Y90 
Sorafenib Acts through VEGFR-2 Inhibition in a Metastatic Clear-Cell Sarcoma of the Kidney被引量：1
《Journal of Cancer Therapy》2016年第7期487-493,共8页Tu V. Dao Thuan V. Tran Christophe Lebœuf Morad El-Bouchtaoui Jérôme Verine Anne Janin Guilhem Bousquet 
We report here the case of a young patient with metastatic clear-cell sarcoma of the kidney resistant to standard chemotherapy, and with complete response under sorafenib treatment. The remarkable response of her tumo...
关键词：Tyrosine-Kinase Inhibitor VEGFR2 Metastases Clear-Cell Sarcoma of the Kidney 
Better Management of Adverse Events Favors Sorafenib Treatment of HCC Patients and Impact on Survival
《Journal of Cancer Therapy》2016年第4期275-284,共10页Regiane S. S. M. Alencar Luciana Kikuchi Cláudia M. Tani Aline L. Chagas Cinira C. Camargo Túlio E. F. Pfiffer Paulo M. G. Hoff Flair J. Carrilho 
Introduction: Sorafenib is an orally active multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma (HCC) and is the only systemic treatment associated with a survival benefit in advanced...
关键词：Management of Adverse Event Hepatocellular Carcinoma Sorafenib Therapy Predictors of Overall Survival Dermatologic Adverse Event 
Sorafenib after Arterial Chemoembolization in Child-Pugh A and B Cirrhotic Patients with Intermediate Hepatocellular Carcinoma: A Retrospective Analysis
《Journal of Cancer Therapy》2015年第3期286-292,共7页Fernando Gomes Romeiro Luciana Yumi Odani Sigahi Matheus Alvarez Fabio da Silva Yamashiro Fábio Cardoso de Carvalho Leonardo Pelafsky Talles Bazeia Lima Letícia de Campos Franzoni José Ricardo de Arruda Miranda Giovanni Faria Silva 
Introduction: Hepatocellular carcinoma (HCC) is a leading cause of mortality among cirrhotic patients, and current guidelines recommend single-treatment modalities according to patient and liver disease classification...
关键词：HEPATOCELLULAR Carcinoma CIRRHOSIS Arterial CHEMOEMBOLIZATION SORAFENIB 
Time to Progression of AFP(TPA)as a Predictor of Survival in Hepatocellular Carcinoma Treated with Sorafenib(SOR)
《Journal of Cancer Therapy》2014年第14期1332-1343,共12页Maria Varela Olegario Castano-Fernandez Marcelo Garrido Lorena Blanco-García Pablo Martínez-Camblor Alicia Mesa-alvarez Carmen Navascues Valle Cadahía-Rodrigo Rafael Menendez de Llano Ramon Perez-alvarez Maria Luisa Gonzalez-Dieguez Manuel Rodríguez 
Background: The standard therapy in advanced hepatocellular carcinoma (HCC) is sorafenib (SOR), which has the inconvenience of toxicity and discontinuation. Patient selection and the use of early markers are critical ...
关键词：Hepatocellular Carcinoma Targeted Therapy AFP SORAFENIB Prognostic Value Overall Survival 
Causes and Stages of Hepatocellular Carcinoma at Patient Presentation at a Tertiary Medical Center in Western Saudi Arabia
《Journal of Cancer Therapy》2014年第14期1303-1310,共8页Shadi Alkhayyat Hind I. Fallatah Hisham O. Akbar Mahmoud S. Al Ahwal Waleed S. Al Ghamdi 
Background: With 748,300 new cases diagnosed every year, hepatocellular carcinoma (HCC) is the 5th?and the 7th?most common cancer among males and females, respectively, and causes 7% of all cancer-related deaths. HCC ...
关键词：Hepatocellular Carcinoma (HCC) CHRONIC HEPATITIS B (CHB) CHRONIC HEPATITIS C (CHC) Radio Frequency Ablation (RFA) SORAFENIB SAUDI ARABIA 
Assessment of the Safety of Olmesartan in Combination with Sorafenib in Mice Bearing Ehrlich’s Ascites Carcinoma
《Journal of Cancer Therapy》2013年第8期1355-1361,共7页Mohammad M. Abd-Alhaseeb Sawsan A. Zaitone Soad H. Abou-El-Ela Yasser M. Moustafa 
Sorafenib was the first multikinase inhibitor to be approved for use in metastatic renal cell carcinoma. Olmesartan medoxomil used in treatment of hypertension and was reported to inhibit angiogenesis in several model...
关键词：MICE Ehrlich’s ASCITES CARCINOMA OLMESARTAN SORAFENIB 
全选清除导出
共1页<1>
检索报告 对象比较 聚类工具 使用帮助 返回顶部